{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:37:14Z","timestamp":1778661434494,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T00:00:00Z","timestamp":1274745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T00:00:00Z","timestamp":1274745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10637-010-9453-z","type":"journal-article","created":{"date-parts":[[2010,5,24]],"date-time":"2010-05-24T04:03:45Z","timestamp":1274673825000},"page":"1143-1155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells"],"prefix":"10.1007","volume":"29","author":[{"given":"Raquel C.","family":"Maia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia C.","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago","family":"de S\u00e1 Bacelar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo J.","family":"Salustiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Felipe R.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9bora L.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Moellman-Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaquip D.","family":"Netto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alcides J.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian M.","family":"Rumjanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo R. R.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,25]]},"reference":[{"key":"9453_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: a new consistent chromossonal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giensa staining. Nature 243:290\u2013293","journal-title":"Nature"},{"key":"9453_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science 247:1079\u20131082","journal-title":"Science"},{"key":"9453_CR3","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112:4808\u20134817","journal-title":"Blood"},{"key":"9453_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet 4:75\u201385","journal-title":"Lancet"},{"key":"9453_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","volume":"249","author":"JV Melo","year":"2007","unstructured":"Melo JV, Chuah C (2007) Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 249:121\u2013132","journal-title":"Cancer Lett"},{"key":"9453_CR6","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarini","year":"2006","unstructured":"Baccarini M, Saglio G, Goldman JM, Hochhaus A, Simonsson B, Appelbaum E et al (2006) Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia-net. Blood 108:1809\u20131820","journal-title":"Blood"},{"key":"9453_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","volume":"274","author":"G Volpe","year":"2009","unstructured":"Volpe G, Panuzzo C, Ulisciani S, Cilloni D (2009) Imatinib resistance in CML. Cancer Lett 274:1\u20139","journal-title":"Cancer Lett"},{"key":"9453_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/sj.leu.2404137","volume":"20","author":"JS Krorashad","year":"2006","unstructured":"Krorashad JS, Anabd M, Marin D, Saunders S, Al-Jabary T, Iqbal A et al (2006) The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 20:658\u2013663","journal-title":"Leukemia"},{"key":"9453_CR9","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104:3739\u20133745","journal-title":"Blood"},{"key":"9453_CR10","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1073\/pnas.0602402103","volume":"103","author":"HG Wendel","year":"2006","unstructured":"Wendel HG, de Stanchina E, Cepero E, Ray S, Emig M, Fridman JS et al (2006) Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci USA 103:7444\u20137449","journal-title":"Proc Natl Acad Sci USA"},{"key":"9453_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.leu.2403257","volume":"18","author":"T Illmer","year":"2004","unstructured":"Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschl\u00e3gel U, von Bonin M et al (2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18:401\u2013408","journal-title":"Leukemia"},{"key":"9453_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1023\/B:APPT.0000045788.61012.b2","volume":"9","author":"A Wrzesie\u0144-Ku\u015b","year":"2004","unstructured":"Wrzesie\u0144-Ku\u015b A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T (2004) The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis 9:705\u2013715","journal-title":"Apoptosis"},{"key":"9453_CR13","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","volume":"30","author":"DL Deremer","year":"2008","unstructured":"Deremer DL, Ustun C, Natarajan K (2008) Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leucemia. Clin Ther 30:1956\u20131975","journal-title":"Clin Ther"},{"key":"9453_CR14","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","volume":"68","author":"F-X Mahon","year":"2008","unstructured":"Mahon F-X, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F et al (2008) Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68:9809\u20139816","journal-title":"Cancer Res"},{"key":"9453_CR15","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","volume":"101","author":"F-X Mahon","year":"2003","unstructured":"Mahon F-X, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101:2368\u20132373","journal-title":"Blood"},{"key":"9453_CR16","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.ejmech.2008.01.027","volume":"44","author":"CD Netto","year":"2009","unstructured":"Netto CD, Santos ES, Castro CP, da Silva AJ, Rumjanek VM, Costa PR (2009) (+\/\u2212)-3, 4-Dihydroxy-8, 9-methylenedioxypterocarpan and derivatives: cytotoxic effect on human leukemia cell lines. Eur J Med Chem 44:920\u2013925","journal-title":"Eur J Med Chem"},{"key":"9453_CR17","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.bmc.2009.12.073","volume":"18","author":"CD Netto","year":"2010","unstructured":"Netto CD, Silva AJ, Salustiano EJ, Rica IG, Cavalcante MC, Rumjanek VM et al (2010) New Pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-a modulation in human PBMC cells. Bioorg Med Chem 18:1610\u20131616","journal-title":"Bioorg Med Chem"},{"key":"9453_CR18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/j.1751-1097.1999.tb03348.x","volume":"69","author":"GS Trindade","year":"1999","unstructured":"Trindade GS, Capella MA, Capella LS, Affonso-Mitidieri OR, Rumjanek VM (1999) Differences in sensitivity to UVC, UVB and UVA radiation of a multidrug-resistant cell line overexpressing P-glycoprotein. Photochem Photobiol 69:694\u2013699","journal-title":"Photochem Photobiol"},{"key":"9453_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1590\/S0001-37652001000100007","volume":"73","author":"VM Rumjanek","year":"2001","unstructured":"Rumjanek VM, Trindade GS, Wagner-Souza K, de-Oliveira MC, Marques-Santos LF, Maia RC et al (2001) Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1. An Acad Bras Cien 73:57\u201369","journal-title":"An Acad Bras Cien"},{"key":"9453_CR20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarini M, Tura S, Gomez GA, Robertson JE et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63:789\u2013799","journal-title":"Blood"},{"key":"9453_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and citotoxicity assays. J Immunol Meth 65:55\u201363","journal-title":"J Immunol Meth"},{"key":"9453_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10637-007-9064-5","volume":"25","author":"FC Vasconcelos","year":"2007","unstructured":"Vasconcelos FC, Gattass CR, Rumjanek VM, Maia RC (2007) Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile. Invest New Drugs 25:525\u2013533","journal-title":"Invest New Drugs"},{"key":"9453_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.leukres.2006.07.016","volume":"31","author":"FC Vasconcelos","year":"2007","unstructured":"Vasconcelos FC, Cavalcanti GB Jr, Silva KL, de Meis E, Kwee JK, Rumjanek VM et al (2007) Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res 31:445\u2013454","journal-title":"Leuk Res"},{"key":"9453_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/(SICI)1097-0320(19981215)34:6<248::AID-CYTO2>3.0.CO;2-X","volume":"34","author":"S Huet","year":"1998","unstructured":"Huet S, Marie J-P, Gualde N, Robert J (1998) Reference method for detection of P-gp mediated multi-drug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network. Cytometry 34:248\u2013256","journal-title":"Cytometry"},{"key":"9453_CR25","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood.V91.12.4480","volume":"91","author":"O Legrand","year":"1998","unstructured":"Legrand O, Simonin G, Perrot J-Y, Zittoun R, Marie JP (1998) Pgp and MRP activities using calcein-AM are prognostic factors in acute myeloid leukemia patients. Blood 91:4480\u20134488","journal-title":"Blood"},{"key":"9453_CR26","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood.V93.12.4086","volume":"93","author":"XF Hu","year":"1999","unstructured":"Hu XF, Slater A, Kantharidis P, Rischin S, Juneja S, Rossi R et al (1999) Altered multi-drug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 93:4086\u20134095","journal-title":"Blood"},{"key":"9453_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cyto.b.20013","volume":"61B","author":"GB Cavalcanti Jr","year":"2004","unstructured":"Cavalcanti GB Jr, Vasconcelos FC, Pinto GF, Scheiner MA, Dobbin JA, Klumb CE et al (2004) Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry 61B:1\u20138","journal-title":"Cytometry"},{"key":"9453_CR28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265\u2013275","journal-title":"J Biol Chem"},{"key":"9453_CR29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/CAD.0b013e3283140c6f","volume":"19","author":"JK Kwee","year":"2008","unstructured":"Kwee JK, Luque DG, Ferreira ACS, Vasconcelos FC, Silva KL, Klumb CE et al (2008) Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation. Anticancer Drugs 19:975\u2013981","journal-title":"Anticancer Drugs"},{"key":"9453_CR30","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1016\/S0021-9258(17)31596-X","volume":"269","author":"T Oda","year":"1994","unstructured":"Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ (1994) CrkL is the major tyrosine-phosphorulated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269:22925\u201322928","journal-title":"J Biol Chem"},{"key":"9453_CR31","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","volume":"106","author":"D White","year":"2005","unstructured":"White D, Saunders V, Lyons AB, Branford S, Grigg A, Bik To L et al (2005) In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 106:2520\u20132526","journal-title":"Blood"},{"key":"9453_CR32","doi-asserted-by":"crossref","unstructured":"Bixby D, Talpaz M (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 461\u2013476","DOI":"10.1182\/asheducation-2009.1.461"},{"key":"9453_CR33","first-page":"F1","volume":"1551","author":"M Z\u00f6rnig","year":"2001","unstructured":"Z\u00f6rnig M, Hueber A-O, Baum W, Evan G (2001) Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 1551:F1\u2013F37","journal-title":"Biochim Biophys Acta"},{"key":"9453_CR34","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","volume":"107","author":"BZ Carter","year":"2006","unstructured":"Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T et al (2006) Regulation of survivin expression through Bcr-Abl\/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 107:1555\u20131563","journal-title":"Blood"},{"key":"9453_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.canlet.2006.12.020","volume":"249","author":"MJ Duffy","year":"2007","unstructured":"Duffy MJ, O\u2019Donovan N, Brennan DJ, Gallagher WM, Ryan BM (2007) Survivin: a promising tumor biomarker. Cancer Lett 249:49\u201360","journal-title":"Cancer Lett"},{"key":"9453_CR36","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/sj.cdd.4401091","volume":"9","author":"C Mahotka","year":"2001","unstructured":"Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE et al (2001) Differencial subcellular localization of functionally divergent splice variants. Cell Death Differ 9:1334\u20131342","journal-title":"Cell Death Differ"},{"key":"9453_CR37","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1248\/bpb.30.2279","volume":"30","author":"L Feng","year":"2007","unstructured":"Feng L, Xie Z-H, Cai G-P, Jiang Y-Y (2007) The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells. Biol Pharm Bull 30:2279\u20132283","journal-title":"Biol Pharm Bull"},{"key":"9453_CR38","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V93.3.1075","volume":"93","author":"RW Johnstone","year":"1999","unstructured":"Johnstone RW, Cretney E, Smyth MJ (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93:1075\u20131085","journal-title":"Blood"},{"key":"9453_CR39","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.cdd.4401440","volume":"11","author":"KM Tainton","year":"2004","unstructured":"Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM et al (2004) Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ 11:1028\u20131037","journal-title":"Cell Death Differ"},{"key":"9453_CR40","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","volume":"98","author":"F Binifazi","year":"2001","unstructured":"Binifazi F, de Vivo A, Rosti G et al (2001) Chronic myeloid leukemia and interferon \u03b1: a study of complete cytogenetic responders. Blood 98:3074\u20133081","journal-title":"Blood"},{"key":"9453_CR41","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1182\/blood-2007-08-103499","volume":"113","author":"F Castagnetti","year":"2009","unstructured":"Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S et al (2009) Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GINEMA CML Working Party. Blood 113:3428\u20133434","journal-title":"Blood"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9453-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9453-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:01:03Z","timestamp":1678510863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9453-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,25]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9453"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9453-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,25]]},"assertion":[{"value":"21 January 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}